Cardiorenal syndrome(CRS)is a clinical syndrome characterized by hemodynamic changes,abnormal continuous activation of neurohumoral factors,inflammation,oxidative stress and anemia.Recent large clinical studies have consistently shown that sodium-glucose co-transporter 2 inhibitor(SGLT2i),a novel oral hypoglycemic agent,provides benefits for both cardiovascular and kidney diseases.Therefore,SGLT2i expected to be an important treatment to improve the prognosis of patients with CRS.This article aims to summarize the recent evidence of cardiorenal benefit from SGLT2i in large clinical trials and explore the potential mechanism of this benefit in treating cardiorenal syndrome,independent of its hypoglycemic effect,from the pathophysiological perspective.
维普
万方数据
